PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin
Background The success of new targeted cancer therapies has been dependent on the identification of tumor-specific antigens. Podocalyxin (Podxl) is upregulated on tumors with high metastatic index and its presence is associated with poor outcome, thus emerging as an important prognostic and theragno...
Saved in:
| Main Authors: | Blake Gilks, Martin Köbel, Diana Canals Hernaez, Michael R Hughes, Pamela Dean, Peter Bergqvist, Ismael Samudio, Ola Blixt, Katharina Wiedemeyer, Yicong Li, Chris Bond, Eric Cruz, Calvin D Roskelley, Kelly M McNagny |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001128.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Podocalyxin and kidney diseases
by: I. Kostovska
Published: (2025-04-01) -
PENGARUH HARGA DAN LOKASI TERHADAP KEPUTUSAN PEMBELIAN DI TOKO PODO JODO
by: Christine Megawati, et al.
Published: (2020-09-01) -
Relationship between Elevated Maternal Serum Podocalyxin Concentrations with Blood Pressure Values and Routine Laboratory Parameters in Preeclampsia
by: Nikola Popovski, et al.
Published: (2021-12-01) -
Neuroprotective effect of the combination therapy of melatonin and URB447 after neonatal hypoxia-ischemia
by: Marc Chillida, et al.
Published: (2025-07-01) -
Correction: The SGK3-triggered ubiquitin-proteasome degradation of podocalyxin (PC) and ezrin in podocytes was associated with the stability of the PC/ezrin complex
by: Ya-Pei Yuan, et al.
Published: (2025-04-01)